Furthermore, IDH-wildtype GBM with methylated MGMT has greater sensitivity to temozolomide chemotherapy than those with unmethylated MGMT, which can prolong the survival time of IDH-wildtype GBM by 7.2–8.9 months [6,7]. This evidence concerns the gene MGMT and glioblastoma.